This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Alzheimer's disease (AD); Parkinson's disease (PD)

Heparan sulfate proteoglycan (HSPG)

In vitro and mouse studies suggest inhibiting the interaction between microtubule-associated protein-t (MAPT; TAU; FTDP-17) fibrils and HSPG could help treat AD. In AD and PD, pathogenic TAU and a-synuclein (SNCA) fibrils spread by being released and then subsequently internalized by connected neurons. In cultured mouse primary neurons and neural precursor cells, extracellular Tau fibrils bound Hspg on cell surfaces. In neuronal precursor cells and in cortices of wild-type mice, inhibition of the interaction between Hspg and Tau or Snca with a heparin mimetic decreased their internalization and aggregation compared with no treatment. Next steps include designing small molecule inhibitors of the HSPG-TAU interaction (see Tamping down TAU, page 6).

SciBX 6(32); doi:10.1038/scibx.2013.868
Published online Aug. 22, 2013

Patent application filed; unavailable for licensing

Holmes, B.B. et al. Proc. Natl. Acad. Sci. USA; published online July 29, 2013;
doi:10.1073/pnas.1301440110
Contact: Marc I. Diamond, Washington University in St. Louis School of Medicine, St. Louis, Mo.
e-mail:
diamondm@neuro.wustl.edu